10x Genomics to Analyze 1,000 Autoimmune Cases, Establish CLIA Lab and Launch 20,000-Sample AI Oncology Project
10x Genomics will partner with Dana-Farber to analyze hundreds of tumor samples using its Chromium Flex platform and establish a CLIA-certified lab to develop diagnostics. It will also profile blood from 1,000 autoimmune patients with Brigham & Women’s and generate 20,000-sample AI spatial and single-cell data with the Cancer Research Institute.
1. Collaboration with Dana-Farber Cancer Institute
10x Genomics today announced a multi-year research partnership with Dana-Farber Cancer Institute to profile tumor samples from several hundred patients across major solid tumor types. Leveraging the Chromium Flex single-cell assay and Xenium spatial platform, the initiative will generate high-resolution molecular maps that integrate cellular composition and spatial context. By comparing these profiles with clinical outcomes for therapies including antibody-drug conjugates, radioligand therapies, bispecific antibodies and immune checkpoint inhibitors, the collaboration aims to identify biomarkers linked to response, resistance and disease progression.
2. Study Design and Expected Outputs
Investigators will analyze tumor microenvironment features—such as immune contexture, target expression patterns and indicators of therapeutic sensitivity—across patient cohorts treated with next-generation oncology agents. The project will include standardized sample processing workflows, bioinformatic pipelines for single-cell and spatial data integration, and a pilot evaluation of at least 300 samples to benchmark biomarker discovery. The teams plan to define a clinical reporting framework that translates complex multidimensional data into actionable insights for oncologists.
3. CLIA-Certified Laboratory Build-Out
To support translation of research findings into diagnostic assays, 10x Genomics will establish a CLIA-certified laboratory in Pleasanton, California. The facility will include dedicated instrumentation for assay implementation, analytical validation and high-throughput clinical sample processing. This regulated infrastructure is designed to enable future development of precision oncology tests based on single-cell and spatial technologies, positioning 10x to offer end-to-end services from discovery through clinical deployment.
4. Implications for Investors
By expanding into the diagnostic market and forging a high-profile collaboration with Dana-Farber, 10x Genomics is strengthening its strategic position in precision oncology. The CLIA lab investment represents a capital deployment that could generate new revenue streams from clinical assays and service agreements. Successful biomarker identification and validation may accelerate adoption of 10x’s platforms in both academic and commercial translational research, potentially driving growth in consumables and software usage among biopharma partners.